Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C

Journal of Gastroenterology

Volumn 41, Issue 9, 2006, Pages 862-872

  Oze, Tsugiko ^a   Hiramatsu, Naoki ^a   Kurashige, Nao ^a   Tsuda, Natsuko ^a   Yakushijin, Takayuki ^a   Kanto, Tatsuya ^a   Takehara, Tetsuo ^a   Kasahara, Akinori ^a   Kato, Michio ^b   Yoshihara, Harumasa ^c   Katayama, Kazuhiro ^d   Kubota, Shinji ^e   Hijioka, Taizo ^f   Ishibashi, Kazunobu ^g   Oshita, Masahide ^h   Hagiwara, Hideki ⁱ   Haruna, Yoshimichi ^j   Mita, Eiji ^k   Tamura, Shinji ^a   Hayashi, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c OSAKA ROSAI HOSPITAL   (Japan)

^d OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^e KANSAI ROSAI HOSPITAL   (Japan)

^f MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^g Kaizuka City Hospital   (Japan)

^h OSAKA POLICE HOSPITAL   (Japan)

ⁱ Higashiosaka City General Hospital   (Japan)

^j OSAKA GENERAL MEDICAL CENTER   (Japan)

^k SAISEIKAI SENRI HOSPITAL   (Japan)

more..

Author keywords

"2by 2" standard; Chronic hepatitis C; Interferon and ribavirin combination therapy; Progression of anemia

Indexed keywords

HEMOGLOBIN; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE COURSE; DRUG CLEARANCE; DRUG ERUPTION; DRUG WITHDRAWAL; ECZEMA; FATIGUE; FEMALE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; LIVER; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIVARIATE ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

ADULT; AGED; ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 33750143490     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-006-1858-2     Document Type: Article

References (26)

1. GM Lauer BD Walker 2001 Hepatitis C virus infection N Engl J Med 345 41-52 11439948 1:STN:280:DC%2BD3MzosFGrug%3D%3D 10.1056/ NEJM200107053450107
2. T Poynard P Bedossa P Opolon 1997 Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 825-32 9121257 1:STN:280:ByiB3snosFw%3D 10.1016/S0140-6736(96)07642-8
3. H Hamada H Yatsuhashi K Yano M Daikoku K Arisawa O Inoue 2002 Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C Cancer 95 331-9 12124834 10.1002/ cncr.10662
4. N Hiramatsu N Hayashi A Kasahara H Hagiwara T Takehara Y Haruna 1995 Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha J Hepatol 22 135-42 7790701 1:STN:280:ByqA3M%2FntFQ%3D 10.1016/0168-8278(95)80420-X
5. A Kasahara N Hayashi K Mochizuki M Takayanagi K Yoshioka S Kakumu 1998 Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group Hepatology 27 1394-402 9581697 1:CAS:528:DyaK1cXjtVSjt7Y%3D 10.1002/hep.510270529
6. T Poynard P Marcellin SS Lee C Niederau GS Minuk G Ideo 1998 Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 352 1426-32 9807989 1:CAS:528:DyaK1cXnsVSmsLg%3D 10.1016/S0140-6736(98)07124-4
7. JG McHutchison SC Gordon ER Schiff ML Shiffman WM Lee VK Rustgi 1998 Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 339 1485-92 9819446 1:CAS:528:DyaK1cXnslGmtbs%3D 10.1056/NEJM199811193392101
8. MP Manns JG McHutchison SC Gordon VK Rustgi M Shiffman R Reindollar 2001 Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial Lancet 358 958-65 11583749 1:CAS:528:DC%2BD3MXntF2qtb8%3D 10.1016/S0140-6736(01)06102-5
9. MW Fried ML Shiffman KR Reddy C Smith G Marinos FL Goncales Jr 2002 Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975-82 12324553 1:CAS:528:DC%2BD38Xnt12rtb0%3D 10.1056/NEJMoa020047
10. N Hiramatsu A Kasahara F Nakanishi T Toyama M Tsujii S Tsuji 2004 The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan Hepatol Res 29 142-7 15203077 1:CAS:528:DC%2BD2cXltVGgsrc%3D 10.1016/ j.hepres.2004.03.008
11. HC Bodenheimer Jr KL Lindsay GL Davis JH Lewis SN Thung LB Seeff 1997 Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial Hepatology 26 473-7 9252161 1:CAS:528:DyaK2sXlsVWjur4%3D 10.1002/hep.510260231
12. L De Franceschi G Fattovich F Turrini K Ayi C Brugnara F Manzato 2000 Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage Hepatology 31 997-1004 10733558 1:CAS:528:DC%2BD3cXis1Cks7c%3D 10.1053/ he.2000.5789
13. H Van Vlierbergh JR Delanghe M De Vos G Leroux-Roel 2001 Factors influencing ribavirin-induced hemolysis J Hepatol 34 911-6 11451176 1:STN:280:DC%2BD38%2FitFSisw%3D%3D 10.1016/S0168-8278(01)00029-0
14. G Tappero M Ballare M Farina F Negro 1998 Severe anemia following combined alpha-interferon/ribavirin therapy of chronic hepatitis C J Hepatol 29 1033-4 9875657 1:STN:280:DyaK1M%2FptVygtw%3D%3D 10.1016/ S0168-8278(98)80138-4
15. K Lindahl R Schvarcz A Bruchfeld L Stahle 2004 Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia J Viral Hepat 11 84-7 14738562 1:STN:280:DC%2BD2c%2FotFKrsQ%3D%3D 10.1046/j.1365-2893.2003.00475.x
16. JF Jen P Glue S Gupta D Zambas G Hajian 2000 Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C Ther Drug Monit 22 555-65 11034261 1:CAS:528:DC%2BD3cXnt1Kmtr4%3D 10.1097/00007691-200010000-00010
17. N Kamar E Chatelut E Manolis T Lafont J Izopet L Rostaing 2004 Ribavirin pharmacokinetics in renal and liver transplant patients: Evidence that it depends on renal function Am J Kidney Dis 43 140-6 14712437 1:CAS:528:DC%2BD2cXht1egsrY%3D 10.1053/j.ajkd.2003.09.019
18. Y Karino T Kato T Arakawa S Matsumoto Y Kuwata J Araike 2004 Total clearance (CL/F) of ribavirin is the factor most influencing the incidence of hemolytic anemia during IFN plus ribavirin therapy Hepatology 40 Suppl 1 358
19. Rebetron® Combination Therapy containing Rebetol® (ribavirin, USP) Capsules and Intron® A (interferon alpha-2b, recombinant) Injection prescribing information. Schering Corporation, Kenilworth, NJ. January 2001
20. RG Knodell KG Ishak WC Black TS Chen R Craig N Kaplowitz 1981 Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1 431-5 7308988 1:STN:280:Bi2D2svitlY%3D
21. SJ Hadziyannis H Sette Jr TR Morgan V Balan M Diago P Marcellin 2004 Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346-55 14996676 1:CAS:528:DC%2BD2cXitlOktrg%3D
22. K Lindahl L Stahle A Bruchfeld R Schvarcz 2005 High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C Hepatology 41 275-9 15660393 1:CAS:528:DC%2BD2MXhsVansbg%3D 10.1002/hep.20563
23. I Grattagliano S Russmann VO Palmieri P Juni F Bihl P Portincasa 2004 Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C Hepatology 39 1248-55 15122753 1:CAS:528:DC%2BD2cXks1Sjt7w%3D 10.1002/hep.20208
24. A Bruchfeld K Lindahl R Schvarcz L Stahle 2002 Dosage of ribavirin in patients with hepatitis C should be based on renal function: A population pharmacokinetic analysis Ther Drug Monit 24 701-8 12451285 1:CAS:528:DC%2BD38XptVSitLc%3D 10.1097/00007691-200212000-00004
25. Y Maeda Y Kiribayashi T Moriya A Maruhashi K Omoda S Funakoshi 2004 Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C Ther Drug Monit 26 9-15 14749543 1:CAS:528:DC%2BD2cXkt1ymsQ%3D%3D 10.1097/00007691-200402000-00004
26. N Hiramatsu T Oze N Tsuda N Kurashige K Koga T Toyama 2006 Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? Hepatol Res 35 185-9 16678478 1:CAS:528:DC%2BD28XmslGqtLk%3D